Cite
Population pharmacokinetics and exposure–response relationship of trastuzumab and bevacizumab in early-stage breast cancer.
MLA
Petitcollin, A., et al. “Population Pharmacokinetics and Exposure–response Relationship of Trastuzumab and Bevacizumab in Early-Stage Breast Cancer.” European Journal of Clinical Pharmacology, vol. 77, no. 12, Dec. 2021, pp. 1861–73. EBSCOhost, https://doi.org/10.1007/s00228-021-03179-w.
APA
Petitcollin, A., Azzopardi, N., Pierga, J. Y., Ternant, D., Navarro-Teulon, I., Desvignes, C., Mouret-Reynier, M. A., Coudert, B., & Paintaud, G. (2021). Population pharmacokinetics and exposure–response relationship of trastuzumab and bevacizumab in early-stage breast cancer. European Journal of Clinical Pharmacology, 77(12), 1861–1873. https://doi.org/10.1007/s00228-021-03179-w
Chicago
Petitcollin, A., N. Azzopardi, J. Y. Pierga, D. Ternant, I. Navarro-Teulon, C. Desvignes, M. A. Mouret-Reynier, B. Coudert, and G. Paintaud. 2021. “Population Pharmacokinetics and Exposure–response Relationship of Trastuzumab and Bevacizumab in Early-Stage Breast Cancer.” European Journal of Clinical Pharmacology 77 (12): 1861–73. doi:10.1007/s00228-021-03179-w.